Onconic Therapeutics온코닉테라퓨틱스

Onconic Therapeutics swung from losses in 2024 to strong profits on TTM figures, but the shares are down 35.5% over the past year.

Onconic markets Zastaprazan, an acid blocker for reflux and ulcer disease launched in Korea in October 2024, and is developing the anticancer drug Nesuparib. On trailing figures to H1 2026 it reports revenue of ₩82.2B, operating income of ₩17.3B and net income of ₩19.7B, with cash of ₩58.2B and no borrowings listed. The share price closed at ₩12,770 on 27 October 2026, well below its 52-week high of ₩28,900.

What stands out

• 2025 revenue was ₩53.4B, up from ₩14.8B in 2024, when the company posted an operating loss of ₩4.8B and a net loss of ₩8.1B.
• TTM operating margin is 21.1% and net margin 24%, though the data does not break out what drove the gap between operating and net income.
• The fair value model gives a base value of ₩2,327 per share (bear ₩1,441, bull ₩3,942), well below the current price; the data notes this is a DCF estimate, not an analyst target.
• Valuation is high against peers: P/E of 29.4 and P/B of 6.8, with no dividend paid.
• Recent headlines focus on royalties from Jacuvo and plans to expand anticancer and obesity drug work, plus company statements on Zaqbo tablet data.

What to watch

• Shareholder meeting notices were filed on 16 October 2026; check the agenda and record date in the filings.
• The next half-year or annual results will show whether revenue and profit hold up after the 2025 jump.
• The data does not list pipeline timelines or specific regulatory milestones, so these are worth checking directly in company filings.